Can Allergy Shots Cause Asthma? The Paradox of Treating and Triggering
Allergy shots are a Grade A treatment for allergic asthma — reducing exacerbations, medication needs, and preventing asthma onset in at-risk children. But in patients with uncontrolled asthma (FEV1 below 70% predicted), each injection can provoke bronchospasm by amplifying the sensitized airway's allergic response. Pre-injection FEV1 screening detects unsafe lung function before each shot. SCIT does not create new asthma.
6 peer-reviewed sources
Allergy shots treat allergic asthma but can trigger bronchospasm in patients with pre-existing uncontrolled asthma. FEV1 screening before each injection identifies unsafe asthma control. SCIT does not create new asthma.
Allergy Shots and Asthma: The Dual-Edged Clinical Reality
Allergy shots present a genuine clinical paradox for asthmatic patients — they are both one of the most effective long-term treatments for allergic asthma AND a potential trigger for bronchospasm in patients whose asthma is currently uncontrolled. Both facts are true simultaneously, and understanding both is essential for safe, effective treatment.
On the treatment side: SCIT has Grade A evidence for reducing allergic asthma exacerbations, decreasing medication requirements, lowering bronchial hyperreactivity, and even modifying disease trajectory in children with allergic rhinitis at risk for developing asthma (Jacobsen et al., Allergy, 2007; Abramson et al., Cochrane Database, 2010). For patients with controlled asthma and documented allergen sensitization, SCIT is among the most powerful disease-modifying tools available.
On the risk side: patients with active, uncontrolled asthma (FEV1 below 70% predicted) face significantly elevated risk of bronchospasm from each injection. Bernstein et al. (JACI, 2004) found that fatal reactions to SCIT, though extremely rare (fewer than 1 per 2.5 million injections), are disproportionately associated with uncontrolled asthma. This is why FEV1 measurement before every injection is standard of care for asthmatic SCIT patients.
Accurate allergen testing is especially important for asthmatic patients — knowing your specific IgE sensitivities allows your allergist to formulate treatment targeting the right triggers. At-home allergy testing from providers like Curex provides a comprehensive IgE panel without a clinic visit, ensuring your immunotherapy is built on accurate sensitization data.
Allergy shots treat allergic asthma long-term but require careful pre-injection asthma control monitoring. FEV1 screening before each shot is mandatory for asthmatic patients. Controlled asthma is safe; uncontrolled asthma is not.
How SCIT Both Treats and Can Temporarily Trigger Asthma
Allergic asthma is driven by IgE-mediated sensitization to inhaled allergens. When sensitized patients inhale allergens, mast cells and eosinophils in the airway mucosa release inflammatory mediators — histamine, leukotrienes, prostaglandins — that cause bronchospasm, airway edema, and mucus production. Over time, this leads to airway remodeling and hyperresponsiveness. SCIT addresses this cascade by progressively re-educating the immune response away from IgE-mediated Th2 activity toward Treg-mediated tolerance. After sustained treatment, IgG4 blocking antibodies compete with IgE for allergen binding, mast cell and eosinophil counts in airway mucosa decrease, and airway hyperreactivity diminishes. The risk in uncontrolled asthma: when airways are already inflamed (high eosinophil count, elevated IgE, airway edema), each SCIT injection delivers allergen to a highly sensitized system. The resulting immune activation can be amplified in inflamed airways, triggering bronchospasm. FEV1 measurement before injection detects this state of uncontrolled inflammation.
Pre-Injection FEV1 Screening
Before every allergy shot, asthmatic patients have FEV1 measured by spirometry. If FEV1 is below the patient's established threshold (typically 70% predicted or their personal best), the injection is withheld until asthma control improves. This single screening step prevents the majority of injection-triggered bronchospasm events.
Controlled Asthma: Safe Injection Proceeds
When FEV1 meets the threshold, controlled asthma patients can safely receive SCIT injections with standard observation protocols. In controlled asthma, airway inflammation is suppressed, reducing the risk of amplified mast cell response. Patients must have their rescue inhaler available at the clinic.
Tolerance Builds: Airway Hyperreactivity Decreases
With sustained SCIT at therapeutic dose, IgG4 blocking antibodies and regulatory T cells reduce the IgE-mediated activation of airway mast cells and eosinophils. Bronchial hyperreactivity decreases measurably on bronchoprovocation testing, and exacerbation frequency falls. Long-term SCIT (3–5 years) achieves sustained airway protection.
Long-Term Asthma Disease Modification
After 3–5 years of SCIT, the immune remodeling effect reduces the overall allergic burden driving asthma. The Preventive Allergy Treatment study showed children with allergic rhinitis who received SCIT had approximately 50% lower asthma onset rates than untreated controls (Jacobsen et al., Allergy, 2007). Adults with established asthma show reduced medication requirements and fewer hospitalizations.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youAt-Home SCIT vs SLIT for Asthmatic Patients: Safety Considerations
For asthmatic patients evaluating immunotherapy options, the pre-injection asthma control screening requirement for SCIT is a meaningful consideration. Sublingual immunotherapy carries lower bronchospasm risk and does not require pre-dose lung function monitoring, though SCIT has the strongest evidence base for allergic asthma treatment. For eligible patients with controlled asthma, Curex delivers that same SCIT route as an at-home kit, with a board-certified allergist supervising the first dose and every dose change live over Zoom and a prescribed epinephrine auto-injector confirmed on hand.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT, Curex) — Controlled AsthmaBest | Grade A evidence for allergic asthma; reduces exacerbations and medication use by 3-5 years | 3-5 years | $3,000-10,000 insured | One weekly to monthly self-administered shot at home with Curex; first dose and dose changes supervised live over Zoom, and asthmatic patients confirm asthma control before each dose | Requires controlled asthma (FEV1 >70% predicted); higher risk with uncontrolled asthma |
Allergy Shots (SCIT) — Uncontrolled Asthma | Cannot be safely initiated until asthma is controlled | Must optimize asthma first | Varies | Shots withheld if FEV1 below threshold on injection day | High systemic reaction risk; disproportionate fatal reaction association (Bernstein et al., JACI 2004) |
Sublingual Drops (SLIT) | Disease modification for allergic asthma; lower bronchospasm risk than SCIT | 3-5 years | $2,340 avg 5-yr | At-home daily drops; no pre-dose lung function check required; rescue inhaler always at home | Lower systemic reaction rates; no injection-triggered bronchospasm risk |
- Efficacy
- Grade A evidence for allergic asthma; reduces exacerbations and medication use by 3-5 years
- Duration
- 3-5 years
- Cost (5yr)
- $3,000-10,000 insured
- Convenience
- One weekly to monthly self-administered shot at home with Curex; first dose and dose changes supervised live over Zoom, and asthmatic patients confirm asthma control before each dose
- Safety
- Requires controlled asthma (FEV1 >70% predicted); higher risk with uncontrolled asthma
- Efficacy
- Cannot be safely initiated until asthma is controlled
- Duration
- Must optimize asthma first
- Cost (5yr)
- Varies
- Convenience
- Shots withheld if FEV1 below threshold on injection day
- Safety
- High systemic reaction risk; disproportionate fatal reaction association (Bernstein et al., JACI 2004)
- Efficacy
- Disease modification for allergic asthma; lower bronchospasm risk than SCIT
- Duration
- 3-5 years
- Cost (5yr)
- $2,340 avg 5-yr
- Convenience
- At-home daily drops; no pre-dose lung function check required; rescue inhaler always at home
- Safety
- Lower systemic reaction rates; no injection-triggered bronchospasm risk
For eligible asthmatic patients with controlled asthma, Curex delivers allergy shots as an at-home kit for $129/month — a personalized serum sterile-compounded to USP <797>, prescribed by a board-certified allergist, with your first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector on hand. You give one weekly injection at home where your rescue inhaler is always within reach, and your care team confirms asthma control before dose changes; patients with uncontrolled asthma should stabilize it first or discuss whether sublingual immunotherapy fits better.
See if at-home shots are right for youFrequently asked questions
Can allergy shots cause asthma?
Allergy shots do not create new asthma in people who do not already have asthma. What they can do is trigger bronchospasm in patients with pre-existing allergic asthma that is currently uncontrolled. Patients with active airway inflammation (FEV1 below 70% predicted) face elevated risk of bronchospasm from each injection, because the inflamed airways amplify the immune response to allergen delivery. This is entirely different from causing a new disease — the triggering occurs only in patients with pre-existing allergic airway disease. In patients with controlled asthma, SCIT is a Grade A evidence-based treatment that reduces exacerbations, medication requirements, and long-term disease progression.
Are allergy shots safe for people with asthma?
Allergy shots are safe and effective for asthmatic patients with controlled asthma and documented allergen sensitization — they are in fact one of the most effective treatments for allergic asthma, with Grade A evidence from multiple systematic reviews including Abramson et al. (Cochrane Database, 2010). The safety requirement is asthma control. Standard protocol requires FEV1 measurement before every injection: if lung function is below the patient's established threshold (typically 70% predicted), the shot is withheld until asthma control improves. Patients should always have their rescue inhaler (albuterol) available at the allergy clinic. Uncontrolled asthma is a risk factor for severe systemic reactions, but controlled asthma is not a contraindication.
What is FEV1 and why is it checked before allergy shots?
FEV1 (forced expiratory volume in one second) measures how much air a person can forcibly exhale in the first second of a maximal exhalation. It is the most important single number for assessing real-time asthma control. A lower FEV1 indicates more airway obstruction from bronchospasm and inflammation — the same conditions that amplify risk during SCIT in asthmatic patients. AAAAI/ACAAI practice parameters recommend FEV1 measurement before allergy shot injections in asthmatic patients, with injection withheld if FEV1 falls below approximately 70% of predicted or the patient's personal best. This threshold may be individualized by the allergist. The FEV1 check takes less than two minutes and provides direct, objective data on airway status at the moment of the proposed injection.
Can allergy shots prevent asthma?
Evidence suggests SCIT may prevent or delay asthma development in children with allergic rhinitis who have not yet developed asthma. The Preventive Allergy Treatment (PAT) study followed children with allergic rhinitis and found that those who received SCIT for 3 years had approximately 50% lower rates of asthma onset compared to untreated controls, with benefits persisting at 7-year follow-up (Jacobsen et al., Allergy, 2007). This is potentially the most significant long-term benefit of early SCIT in atopic children — treating rhinitis before it progresses to asthma. For adults with established asthma, SCIT does not prevent asthma (it's already present) but can modify its severity and reduce exacerbation frequency and medication requirements.
What happens if an asthmatic patient has a reaction to allergy shots?
Bronchospasm during SCIT is the primary concern for asthmatic patients. Initial management is inhaled short-acting beta-agonist (albuterol), which the patient's rescue inhaler provides. If bronchospasm is mild to moderate and responds to beta-agonist, the event is documented and dose adjustment is planned for subsequent visits. If bronchospasm is severe — significant respiratory distress, poor response to beta-agonist, oxygen saturation falling — intramuscular epinephrine is administered (epinephrine is both the cardiac and the bronchial emergency medication) and emergency services are called. The clinic should have epinephrine auto-injectors, oxygen, bronchodilators, and a protocol for managing asthma emergencies. Asthmatic patients should NEVER receive shots without their rescue inhaler physically present in the clinic.
Should I tell my allergist if I have asthma before starting allergy shots?
Absolutely — disclosing asthma before starting SCIT is non-negotiable for safety. Your allergist needs to know: whether you have asthma and its current control level, what your baseline FEV1 is (for comparison during future visits), which asthma medications you currently take (rescue and controller), recent asthma exacerbation history, and any history of asthma-related hospitalizations or emergency visits. This information determines whether SCIT can be initiated safely, what pre-injection monitoring is needed, and what dose escalation protocol is appropriate. Patients with uncontrolled or severe asthma may need to optimize asthma management before starting SCIT — or consider whether concurrent dupilumab therapy might stabilize their asthma sufficiently to allow safe SCIT initiation.
Do allergy shots reduce asthma symptoms?
Yes — SCIT has robust evidence for reducing allergic asthma symptoms, decreasing exacerbation frequency, lowering inhaled corticosteroid requirements, and improving quality of life in patients with confirmed allergic asthma. A Cochrane systematic review by Abramson et al. (2010) found SCIT significantly reduced asthma symptom scores and medication use compared to placebo. Long-term SCIT (3–5 years) has been shown to reduce bronchial hyperreactivity on provocation testing — meaning the airways become less reactive to allergens even after treatment ends. Durham et al.'s landmark New England Journal of Medicine study (1999) demonstrated sustained benefit for years after completing immunotherapy. The key condition for these benefits is completing the full 3–5 year treatment course at therapeutic maintenance dose.
Related Articles
How Long Do Allergy Shots Take? Trial vs Reality | Curex
How long do allergy shots take to work? Trials show 12-month benefit, but only 23% complete 3 years. Real-world vs clinical data guide.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT trains your immune system to tolerate allergens over 3-5 years. 85-90% of patients see significant improvement.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.